ID   OTUD5_HUMAN             Reviewed;         571 AA.
AC   Q96G74; B4DGG7; G5E9D7; Q4KMN9; Q8N6T5; Q9H650; Q9H9U0; Q9NT65;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   28-JUN-2023, entry version 160.
DE   RecName: Full=OTU domain-containing protein 5 {ECO:0000305};
DE            EC=3.4.19.12 {ECO:0000269|PubMed:22245969};
DE   AltName: Full=Deubiquitinating enzyme A;
DE            Short=DUBA;
GN   Name=OTUD5 {ECO:0000312|HGNC:HGNC:25402};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 176-571 (ISOFORM 5), AND NUCLEOTIDE SEQUENCE [LARGE
RP   SCALE MRNA] OF 253-571 (ISOFORM 1).
RC   TISSUE=Brain, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Kidney, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 140-571 (ISOFORM 5).
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, INTERACTION WITH TRAF3, AND MUTAGENESIS OF
RP   CYS-224; LEU-542 AND SER-549.
RX   PubMed=17991829; DOI=10.1126/science.1145918;
RA   Kayagaki N., Phung Q., Chan S., Chaudhari R., Quan C., O'Rourke K.M.,
RA   Eby M., Pietras E., Cheng G., Bazan J.F., Zhang Z., Arnott D., Dixit V.M.;
RT   "DUBA: a deubiquitinase that regulates type I interferon production.";
RL   Science 318:1628-1632(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165; SER-177 AND SER-452, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165 AND SER-177, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   FUNCTION.
RX   PubMed=23827681; DOI=10.1016/j.cell.2013.05.046;
RA   Mevissen T.E., Hospenthal M.K., Geurink P.P., Elliott P.R., Akutsu M.,
RA   Arnaudo N., Ekkebus R., Kulathu Y., Wauer T., El Oualid F., Freund S.M.,
RA   Ovaa H., Komander D.;
RT   "OTU deubiquitinases reveal mechanisms of linkage specificity and enable
RT   ubiquitin chain restriction analysis.";
RL   Cell 154:169-184(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-165 AND SER-177, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 172-339.
RG   Structural genomics consortium (SGC);
RT   "The catalytic domain of human OTUD5.";
RL   Submitted (DEC-2010) to the PDB data bank.
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 172-351 IN COMPLEX WITH
RP   UBIQUITIN, CATALYTIC ACTIVITY, FUNCTION, INDUCTION, PHOSPHORYLATION AT
RP   SER-64; SER-165; TYR-175; SER-177 AND THR-507, MUTAGENESIS OF SER-177 AND
RP   CYS-224, ACTIVE SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22245969; DOI=10.1038/nsmb.2206;
RA   Huang O.W., Ma X., Yin J., Flinders J., Maurer T., Kayagaki N., Phung Q.,
RA   Bosanac I., Arnott D., Dixit V.M., Hymowitz S.G., Starovasnik M.A.,
RA   Cochran A.G.;
RT   "Phosphorylation-dependent activity of the deubiquitinase DUBA.";
RL   Nat. Struct. Mol. Biol. 19:171-175(2012).
RN   [18]
RP   FUNCTION, VARIANTS MCAND 161-VAL--GLY-163 DEL; ASN-256; TRP-274; PRO-352;
RP   TRP-404; SER-494 AND TRP-520, CHARACTERIZATION OF VARIANTS MCAND
RP   161-VAL--GLY-163 DEL; ASN-256; TRP-274; PRO-352 AND SER-494, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF CYS-224, AND PHOSPHORYLATION.
RX   PubMed=33523931; DOI=10.1126/sciadv.abe2116;
RG   Undiagnosed Diseases Network;
RA   Beck D.B., Basar M.A., Asmar A.J., Thompson J.J., Oda H., Uehara D.T.,
RA   Saida K., Pajusalu S., Talvik I., D'Souza P., Bodurtha J., Mu W.,
RA   Baranano K.W., Miyake N., Wang R., Kempers M., Tamada T., Nishimura Y.,
RA   Okada S., Kosho T., Dale R., Mitra A., Macnamara E., Matsumoto N.,
RA   Inazawa J., Walkiewicz M., Ounap K., Tifft C.J., Aksentijevich I.,
RA   Kastner D.L., Rocha P.P., Werner A.;
RT   "Linkage-specific deubiquitylation by OTUD5 defines an embryonic pathway
RT   intolerant to genomic variation.";
RL   Sci. Adv. 7:0-0(2021).
CC   -!- FUNCTION: Deubiquitinating enzyme that functions as negative regulator
CC       of the innate immune system. Acts via TRAF3 deubiquitination and
CC       subsequent suppression of type I interferon (IFN) production. Has
CC       peptidase activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin
CC       chains. Can also cleave 'Lys-11'-linked ubiquitin chains (in vitro).
CC       Controls neuroectodermal differentiation through cleaving 'Lys-48'-
CC       linked ubiquitin chains to counteract degradation of select chromatin
CC       regulators such as ARID1A, HDAC2 and HCF1 (PubMed:33523931).
CC       {ECO:0000269|PubMed:17991829, ECO:0000269|PubMed:22245969,
CC       ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:33523931}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:22245969};
CC   -!- ACTIVITY REGULATION: Inhibited by N-ethyl-maleimide (NEM).
CC   -!- SUBUNIT: Interacts with TRAF3. {ECO:0000269|PubMed:17991829,
CC       ECO:0000269|PubMed:22245969}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:33523931}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q96G74-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96G74-2; Sequence=VSP_023195, VSP_023192;
CC       Name=3;
CC         IsoId=Q96G74-3; Sequence=VSP_023192, VSP_023193, VSP_023194;
CC       Name=4;
CC         IsoId=Q96G74-4; Sequence=VSP_045185, VSP_023192;
CC       Name=5;
CC         IsoId=Q96G74-5; Sequence=VSP_023192;
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues, including the liver
CC       and placenta, as well as in peripheral blood leukocytes.
CC       {ECO:0000269|PubMed:17991829}.
CC   -!- INDUCTION: Up-regulated by bacterial lipopolysaccharide (LPS) in bone
CC       marrow-derived macrophages. {ECO:0000269|PubMed:22245969}.
CC   -!- PTM: Phosphorylation at Ser-177 is required for deubiquitinating
CC       activity. {ECO:0000269|PubMed:22245969, ECO:0000269|PubMed:33523931}.
CC   -!- DISEASE: Multiple congenital anomalies-neurodevelopmental syndrome, X-
CC       linked (MCAND) [MIM:301056]: An X-linked recessive, congenital disorder
CC       characterized by central nervous system, craniofacial, cardiac,
CC       skeletal, and genitourinary anomalies. Clinical features include poor
CC       growth, short stature, global developmental delay, impaired
CC       intellectual development, microcephaly, hydrocephalus, hypotonia,
CC       congenital heart defects, hypospadias, and other variable
CC       abnormalities. Brain imaging typically shows ventriculomegaly and thin
CC       corpus callosum. The severity of the disorder is highly variable,
CC       ranging from death in early infancy to survival into the second or
CC       third decade. {ECO:0000269|PubMed:33523931}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Dubious isoform produced through aberrant
CC       splice sites. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Dubious isoform produced through aberrant
CC       splice sites. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the peptidase C85 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14131.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB15416.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK022612; BAB14131.1; ALT_INIT; mRNA.
DR   EMBL; AK026260; BAB15416.1; ALT_INIT; mRNA.
DR   EMBL; AK294590; BAG57778.1; -; mRNA.
DR   EMBL; AF207550; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471224; EAW50724.1; -; Genomic_DNA.
DR   EMBL; BC009917; AAH09917.1; -; mRNA.
DR   EMBL; BC028225; AAH28225.1; -; mRNA.
DR   EMBL; BC098440; AAH98440.1; -; mRNA.
DR   EMBL; AL137509; CAB70778.1; -; mRNA.
DR   CCDS; CCDS14313.1; -. [Q96G74-1]
DR   CCDS; CCDS48104.1; -. [Q96G74-5]
DR   CCDS; CCDS48105.1; -. [Q96G74-4]
DR   PIR; T46265; T46265.
DR   RefSeq; NP_001129629.1; NM_001136157.1. [Q96G74-5]
DR   RefSeq; NP_001129630.1; NM_001136158.1. [Q96G74-5]
DR   RefSeq; NP_001129631.1; NM_001136159.1. [Q96G74-4]
DR   RefSeq; NP_060072.1; NM_017602.3. [Q96G74-1]
DR   RefSeq; XP_006724600.1; XM_006724537.2. [Q96G74-1]
DR   PDB; 3PFY; X-ray; 1.70 A; A=172-344.
DR   PDB; 3TMO; X-ray; 2.20 A; A=172-351.
DR   PDB; 3TMP; X-ray; 1.91 A; A/C/E/G=172-351.
DR   PDBsum; 3PFY; -.
DR   PDBsum; 3TMO; -.
DR   PDBsum; 3TMP; -.
DR   AlphaFoldDB; Q96G74; -.
DR   SMR; Q96G74; -.
DR   BioGRID; 120738; 50.
DR   DIP; DIP-53541N; -.
DR   IntAct; Q96G74; 23.
DR   MINT; Q96G74; -.
DR   STRING; 9606.ENSP00000156084; -.
DR   MEROPS; C85.001; -.
DR   GlyGen; Q96G74; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q96G74; -.
DR   PhosphoSitePlus; Q96G74; -.
DR   BioMuta; OTUD5; -.
DR   DMDM; 74731791; -.
DR   EPD; Q96G74; -.
DR   jPOST; Q96G74; -.
DR   MassIVE; Q96G74; -.
DR   MaxQB; Q96G74; -.
DR   PaxDb; Q96G74; -.
DR   PeptideAtlas; Q96G74; -.
DR   ProteomicsDB; 33910; -.
DR   ProteomicsDB; 4133; -.
DR   ProteomicsDB; 76598; -. [Q96G74-1]
DR   ProteomicsDB; 76599; -. [Q96G74-2]
DR   ProteomicsDB; 76600; -. [Q96G74-3]
DR   TopDownProteomics; Q96G74-2; -. [Q96G74-2]
DR   Antibodypedia; 409; 191 antibodies from 33 providers.
DR   DNASU; 55593; -.
DR   Ensembl; ENST00000156084.8; ENSP00000156084.4; ENSG00000068308.15. [Q96G74-1]
DR   Ensembl; ENST00000376488.8; ENSP00000365671.3; ENSG00000068308.15. [Q96G74-5]
DR   Ensembl; ENST00000396743.7; ENSP00000379969.3; ENSG00000068308.15. [Q96G74-5]
DR   Ensembl; ENST00000428668.2; ENSP00000401629.2; ENSG00000068308.15. [Q96G74-4]
DR   GeneID; 55593; -.
DR   KEGG; hsa:55593; -.
DR   MANE-Select; ENST00000376488.8; ENSP00000365671.3; NM_001136157.2; NP_001129629.1. [Q96G74-5]
DR   UCSC; uc004dlt.5; human. [Q96G74-1]
DR   AGR; HGNC:25402; -.
DR   CTD; 55593; -.
DR   DisGeNET; 55593; -.
DR   GeneCards; OTUD5; -.
DR   HGNC; HGNC:25402; OTUD5.
DR   HPA; ENSG00000068308; Low tissue specificity.
DR   MalaCards; OTUD5; -.
DR   MIM; 300713; gene.
DR   MIM; 301056; phenotype.
DR   neXtProt; NX_Q96G74; -.
DR   OpenTargets; ENSG00000068308; -.
DR   Orphanet; 528084; Non-specific syndromic intellectual disability.
DR   PharmGKB; PA142671217; -.
DR   VEuPathDB; HostDB:ENSG00000068308; -.
DR   eggNOG; KOG2605; Eukaryota.
DR   GeneTree; ENSGT00940000158963; -.
DR   HOGENOM; CLU_021938_0_1_1; -.
DR   InParanoid; Q96G74; -.
DR   OMA; DSHQHTH; -.
DR   OrthoDB; 691582at2759; -.
DR   PhylomeDB; Q96G74; -.
DR   TreeFam; TF326812; -.
DR   PathwayCommons; Q96G74; -.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   SignaLink; Q96G74; -.
DR   SIGNOR; Q96G74; -.
DR   BioGRID-ORCS; 55593; 126 hits in 799 CRISPR screens.
DR   ChiTaRS; OTUD5; human.
DR   GenomeRNAi; 55593; -.
DR   Pharos; Q96G74; Tbio.
DR   PRO; PR:Q96G74; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q96G74; protein.
DR   Bgee; ENSG00000068308; Expressed in upper arm skin and 185 other tissues.
DR   ExpressionAtlas; Q96G74; baseline and differential.
DR   Genevisible; Q96G74; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0101005; F:deubiquitinase activity; IDA:MGI.
DR   GO; GO:1990380; F:K48-linked deubiquitinase activity; IDA:MGI.
DR   GO; GO:0061578; F:K63-linked deubiquitinase activity; IDA:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:FlyBase.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0014033; P:neural crest cell differentiation; IMP:UniProtKB.
DR   GO; GO:1904263; P:positive regulation of TORC1 signaling; IMP:FlyBase.
DR   GO; GO:1904515; P:positive regulation of TORC2 signaling; IMP:FlyBase.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:MGI.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:UniProtKB.
DR   CDD; cd22752; OTU_OTUD5-like; 1.
DR   Gene3D; 3.90.70.80; -; 1.
DR   InterPro; IPR003323; OTU_dom.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   PANTHER; PTHR12419; OTU DOMAIN CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR12419:SF4; OTU DOMAIN-CONTAINING PROTEIN 5; 1.
DR   Pfam; PF02338; OTU; 1.
DR   SUPFAM; SSF54001; Cysteine proteinases; 1.
DR   PROSITE; PS50802; OTU; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Disease variant; Hydrolase;
KW   Intellectual disability; Nucleus; Phosphoprotein; Protease;
KW   Reference proteome; Thiol protease; Ubl conjugation pathway.
FT   CHAIN           1..571
FT                   /note="OTU domain-containing protein 5"
FT                   /id="PRO_0000278223"
FT   DOMAIN          213..341
FT                   /note="OTU"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00139"
FT   REGION          1..111
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          146..175
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          218..224
FT                   /note="Cys-loop"
FT                   /evidence="ECO:0000250"
FT   REGION          273..283
FT                   /note="Variable-loop"
FT                   /evidence="ECO:0000250"
FT   REGION          329..334
FT                   /note="His-loop"
FT                   /evidence="ECO:0000250"
FT   REGION          418..502
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..30
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        93..108
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        420..460
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        221
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        224
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:22245969"
FT   ACT_SITE        334
FT                   /evidence="ECO:0000305|PubMed:22245969"
FT   MOD_RES         64
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22245969,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22245969,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         175
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:22245969"
FT   MOD_RES         177
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22245969,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         507
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:22245969"
FT   VAR_SEQ         1..217
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045185"
FT   VAR_SEQ         17..40
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_023195"
FT   VAR_SEQ         304..308
FT                   /note="Missing (in isoform 2, isoform 3, isoform 4 and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005"
FT                   /id="VSP_023192"
FT   VAR_SEQ         563..566
FT                   /note="HRDP -> PCRC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_023193"
FT   VAR_SEQ         567..571
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_023194"
FT   VARIANT         161..163
FT                   /note="Missing (in MCAND; reduced cleavage activity towards
FT                   'K-48'-chains but not 'K-63'-chains; no effect on
FT                   phosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085336"
FT   VARIANT         256
FT                   /note="D -> N (in MCAND; reduced cleavage activity towards
FT                   'K-63'- and 'K-48'-chains; no effect on phosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085337"
FT   VARIANT         274
FT                   /note="R -> W (in MCAND; partial mislocation at the
FT                   cytoplasm; reduced cleavage activity towards 'K-63'- and
FT                   'K-48'-chains; no effect on phosphorylation;
FT                   dbSNP:rs2063805506)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085338"
FT   VARIANT         352
FT                   /note="L -> P (in MCAND; in mice embryo the mutation is
FT                   lethal; reduced cleavage activity towards 'K-48'-chains but
FT                   not 'K-63'-chains; no effect on nuclear location; no effect
FT                   on phosphorylation; dbSNP:rs2063801903)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085339"
FT   VARIANT         404
FT                   /note="R -> W (in MCAND; unknown pathological significance;
FT                   dbSNP:rs2063659512)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085340"
FT   VARIANT         494
FT                   /note="G -> S (in MCAND; decreased mRNA and protein levels;
FT                   no effect on cleavage activity towards 'K-48'-chains but
FT                   not 'K-63'-chains; in mice embryo the mutation is lethal;
FT                   no effect on phosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085341"
FT   VARIANT         520
FT                   /note="R -> W (in MCAND; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:33523931"
FT                   /id="VAR_085342"
FT   MUTAGEN         177
FT                   /note="S->D,E: Loss of deubiquitinase activity. Abolishes
FT                   activation by protein kinases."
FT                   /evidence="ECO:0000269|PubMed:22245969"
FT   MUTAGEN         224
FT                   /note="C->S: Loss of deubiquitinase activity. Loss of
FT                   suppression of IFN production. No effect on nuclear
FT                   location."
FT                   /evidence="ECO:0000269|PubMed:17991829,
FT                   ECO:0000269|PubMed:22245969, ECO:0000269|PubMed:33523931"
FT   MUTAGEN         542
FT                   /note="L->A: Loss of 'K-48'- and 'K-63'-linked
FT                   polyubiquitin chain binding. Partial loss of TRAF3
FT                   deubiquitination; when associated with A-549."
FT                   /evidence="ECO:0000269|PubMed:17991829"
FT   MUTAGEN         549
FT                   /note="S->A: Loss of 'K-48'- and 'K-63'-linked
FT                   polyubiquitin chain binding. Partial loss of TRAF3
FT                   deubiquitination; when associated with A-542."
FT                   /evidence="ECO:0000269|PubMed:17991829"
FT   HELIX           178..180
FT                   /evidence="ECO:0007829|PDB:3TMP"
FT   HELIX           181..186
FT                   /evidence="ECO:0007829|PDB:3TMP"
FT   HELIX           193..211
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   HELIX           224..234
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   HELIX           237..239
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   HELIX           240..253
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   HELIX           255..258
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   HELIX           259..261
FT                   /evidence="ECO:0007829|PDB:3TMP"
FT   HELIX           266..273
FT                   /evidence="ECO:0007829|PDB:3TMP"
FT   HELIX           282..292
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   STRAND          296..301
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:3TMO"
FT   STRAND          311..314
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   STRAND          325..330
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   TURN            331..333
FT                   /evidence="ECO:0007829|PDB:3PFY"
FT   STRAND          334..339
FT                   /evidence="ECO:0007829|PDB:3PFY"
SQ   SEQUENCE   571 AA;  60626 MW;  F4B2B385B84ABC46 CRC64;
     MTILPKKKPP PPDADPANEP PPPGPMPPAP RRGGGVGVGG GGTGVGGGDR DRDSGVVGAR
     PRASPPPQGP LPGPPGALHR WALAVPPGAV AGPRPQQASP PPCGGPGGPG GGPGDALGAA
     AAGVGAAGVV VGVGGAVGVG GCCSGPGHSK RRRQAPGVGA VGGGSPEREE VGAGYNSEDE
     YEAAAARIEA MDPATVEQQE HWFEKALRDK KGFIIKQMKE DGACLFRAVA DQVYGDQDMH
     EVVRKHCMDY LMKNADYFSN YVTEDFTTYI NRKRKNNCHG NHIEMQAMAE MYNRPVEVYQ
     YSTGTSAVEP INTFHGIHQN EDEPIRVSYH RNIHYNSVVN PNKATIGVGL GLPSFKPGFA
     EQSLMKNAIK TSEESWIEQQ MLEDKKRATD WEATNEAIEE QVARESYLQW LRDQEKQARQ
     VRGPSQPRKA SATCSSATAA ASSGLEEWTS RSPRQRSSAS SPEHPELHAE LGMKPPSPGT
     VLALAKPPSP CAPGTSSQFS AGADRATSPL VSLYPALECR ALIQQMSPSA FGLNDWDDDE
     ILASVLAVSQ QEYLDSMKKN KVHRDPPPDK S
//
